Pharmacokinetics and Drug Resistance in Tuberculosis Treatment

Pharmacokinetics examines how anti-tuberculosis agents are absorbed, distributed to sites of infection, metabolised and eliminated, while pharmacodynamics relates these exposures to microbial kill and suppression of resistance. Effective treatment requires achieving drug concentrations above the pathogen’s minimum inhibitory concentration throughout the course of therapy and within diverse lesion compartments. Suboptimal exposures—owing to variable absorption, inadequate tissue penetration, host metabolism or erratic adherence—can foster the emergence of resistant Mycobacterium tuberculosis strains via selection of resistant mutants or upregulation of efflux systems. Multi-drug-resistant and extensively drug-resistant tuberculosis remain global challenges, prolonging treatment duration and increasing morbidity. Advances in hollow-fibre infection models, Monte Carlo simulations and integrated PK/PD modelling now enable precise dose optimisation, susceptibility breakpoint determination and prediction of sterilising activity. A deeper understanding of lesion pharmacokinetics, pathogen genetic fitness and compensatory mutations offers pathways to refine regimens, reduce toxicity and curb transmission.

Research from Nature Portfolio

Recent studies have clarified why resistance to certain drugs remains remarkably rare and how compensatory mechanisms mitigate the fitness cost of primary resistance mutations. One investigation combined bacterial genetics, genomics, biochemical assays and in vitro and in vivo fitness analyses to reveal the ultra-low rate of emergence of mutations against a key second-line agent, and identified genetic pathways that restore growth despite resistance-conferring changes. Another work developed a hollow-fibre infection model that faithfully mimics lung lesion pharmacokinetics for first-line combination therapies. By simulating plasma and lesion drug profiles for multiple agents, researchers established practical protocols and a user-friendly interface to translate in vivo pharmacokinetic parameters into in vitro pump settings, thereby improving prediction of treatment efficacy at the site of disease.

Pharmacokinetics and Drug Resistance in Tuberculosis Treatment publication trend

The graph below shows the total number of articles in pharmacokinetics and drug resistance in tuberculosis treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Pharmacokinetics (PK): Study of drug absorption, distribution, metabolism and excretion.

Pharmacodynamics (PD): Relationship between drug concentration and its antimicrobial effect.

Minimum inhibitory concentration (MIC): Lowest drug concentration that prevents visible bacterial growth.

Hollow-fibre system: In vitro infection model that simulates human pharmacokinetic profiles for antimicrobial testing.

Area under the concentration–time curve (AUC): Integral of plasma drug concentration over time, reflecting overall exposure.

AUC/MIC ratio: PK/PD index correlating drug exposure to antimicrobial potency and suppression of resistance.

References

1. Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes. Nature Communications (2019).
2. Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection. Scientific Reports (2019).
3. Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies. Frontiers in Pharmacology (2022).
4. Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy (2020).
5. Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis. Frontiers in Pharmacology (2021).